Navigation Links
Seahorse Bioscience to Present Novel Cellular Bioenergetics Data in Collaboration with University of Nebraska at AACR Metabolism and Cancer Conference
Date:9/9/2009

NORTH BILLERICA, Mass., Sept. 9 /PRNewswire/ -- Seahorse Bioscience, Inc., the leader in the design and development of instruments for assessing cellular bioenergetics, today announced it will present data with the University of Nebraska demonstrating the power of the XF Extracellular Flux Analyzer in revealing the effects of KSR1 and nutrients on oxidative phosphorylation and aerobic glycolysis in cancer cells. The data will appear in two posters at the AACR Metabolism and Cancer Conference to be held September 13-16th in La Jolla, CA.

The first poster, "The molecular scaffold, Kinase Suppressor of Ras 1 (KSR1), potentiates H-RasV12 induced transformation and expands cellular capacity for glycolysis and oxidative phosphorylation," reveals unexpected changes in glucose uptake and redirection from bioenergetic pathways to biosynthetic pathways with KSR1 expression in MEF, suggesting that KSR1 optimizes substrate metabolism in Ras-transformed cells. "Our collaboration with Seahorse allowed us to take gene array data and connect it directly to cellular metabolic activity, "observed Dr. Rob Lewis, Professor in the Eppley Cancer Institute at the University of Nebraska Medical Center and poster co-author. "We are now actively exploring new connections among genes, metabolism, and oncogenesis."

The second poster, "Monitoring the flux of glucose, glutamine and metabolic intermediates in tumor cells: excessive nutrients are necessary for cellular metabolic transformation," shows the effects of excessive nutrients in tumor cells beyond the Warburg effect, including shifts in substrate flux in both the bioenergetic and the biosynthetic pathways.

"We undertook this collaboration to show how the XF may be used to uncover novel metabolic aspects of various cancers," stated Dr. Min Wu, Director of Applications Development with Seahorse Bioscience and co-author on both posters. "The work of Dr. Lewis's shows the importance of genes in mitogen signaling pathways in malignant transformation, while my lab is beginning to show the importance of nutrients in determining the outcomes of cancer phenotypes. This would have been very difficult to detect without the XF Analyzer."

About Seahorse Bioscience

Seahorse XF instruments are the new standard in cellular bioenergetic measurements. Scientists worldwide use these tools to advance their research in understanding the role of mitochondrial function in obesity, diabetes, ageing, cancer, cardiovascular function and safety toxicity. Founded in 2001, Seahorse is headquartered in Billerica, MA. For more information, please visit http://www.seahorsebio.com.

    Seahorse Bioscience, Inc.
    Media Contact: Cynthia Egan
    Phone: 978.671.1610


'/>"/>
SOURCE Seahorse Bioscience, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Seahorse Bioscience Appoints Former Molecular Devices Executive Dr. Joseph D. Keegan to Board of Directors
2. Seahorse Bioscience Receives Poster Award from the European Association for the Study of Obesity
3. Seahorse Bioscience, Inc. Acquires BioProcessors Corp.
4. New Cellular Bioenergetics Workshops Series Inaugurated by Seahorse Bioscience with Two of the Worlds Leading Bioenergetics Researchers
5. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
6. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
7. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
8. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
9. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
10. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
11. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)... SILVER SPRING, Md. , June 23, 2016 ... evidence collected from the crime scene to track the criminal ... sick, and the U.S. Food and Drug Administration (FDA) uses ... Sound far-fetched? It,s not. ... whole genome sequencing to support investigations of foodborne illnesses. Put ...
(Date:6/23/2016)... ... 2016 , ... Charm Sciences, Inc. is pleased to announce ... Research Institute approval 061601. , “This is another AOAC-RI approval of the Peel ... President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably to ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge ... envision new ways to harness living systems and biotechnology, ... Art (MoMA) in New York City ... 130 participating students, showcased projects at MoMA,s Celeste Bartos ... Paola Antonelli , MoMA,s senior curator of architecture and ...
Breaking Biology Technology:
(Date:5/3/2016)...  Neurotechnology, a provider of high-precision biometric identification ... Identification System (ABIS) , a complete system for ... can process multiple complex biometric transactions with high ... face or iris biometrics. It leverages the core ... MegaMatcher Accelerator , which have been used in ...
(Date:4/26/2016)... LONDON , April 26, 2016 /PRNewswire/ ... Systems, a product subsidiary of Infosys (NYSE: ... partnership to integrate the Onegini mobile security platform ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration ... security to access and transact across channels. Using ...
(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
Breaking Biology News(10 mins):